Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
Can Alto Neuroscience’s ALTO-207 change treatment-resistant depression care? Read what the new Phase 2b trial could mean for psychiatry.
Pharma & Biotech
Pharma & Biotech
Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression
Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.
Medical Devices & Diagnostics
FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?
Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.
Pharma & Biotech
Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope
Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double
Pharma & Biotech
Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.
Pharma & Biotech
HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.
Pharma & Biotech
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.
Pharma & Biotech
Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy
Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical